Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation

Journal of Cancer Research and Clinical Oncology

Volumn 144, Issue 2, 2018, Pages 403-414

  Trevisani, Franco ^a   Brandi, Giovanni ^a   Garuti, Francesca ^a   Barbera, Maria Aurelia ^a   Tortora, Raffaella ^b   Casadei Gardini, Andrea ^c   Granito, Alessandro ^a   Tovoli, Francesco ^a   De Lorenzo, Stefania ^a   Inghilesi, Andrea Lorenzo ^d   Foschi, Francesco Giuseppe ^e   Bernardi, Mauro ^a   Marra, Fabio ^d   Sacco, Rodolfo ^f   Di Costanzo, Giovan Giuseppe ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e Ospedale per gli Infermi di Faenza   (Italy)

^f UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Hepatocellular carcinoma; Metronomic capecitabine; Second line chemotherapy; Survival; Toxicity

Indexed keywords

CAPECITABINE; SORAFENIB; ANTINEOPLASTIC ANTIMETABOLITE; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL OUTCOME; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FUNCTIONAL STATUS; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METRONOMIC CHEMOTHERAPY; MORTALITY RISK; MULTICENTER STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROPENSITY SCORE; RADIOGRAPHY; RASH; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR THROMBUS; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; VOMITING; ANALOGS AND DERIVATIVES; LIVER TUMOR; METRONOMIC DRUG ADMINISTRATION; SURVIVAL RATE;

ADMINISTRATION, METRONOMIC; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CAPECITABINE; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 85038115440     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-017-2556-6     Document Type: Article

References (35)

1. Abdel-Rahman O, Abdel-Wahab M, Shaker M, Abdel-Wahab S, Elbassiony M, Ellithy M (2013) Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol 30:655
2. Brandi G, de Rosa F, Bolondi L, Agostini V, Di Girolamo S, Nobili E, Biasco G (2010) Durable complete response of hepatocellular carcinoma after metronomic capecitabine. Tumori 96:1028–1030
3. Brandi G, de Rosa F, Agostini V, di Girolamo S, Andreone P, Bolondi L, Serra C, Sama C, Golfieri R, Gramenzi A, Cucchetti A, Pinna AD, Trevisani F, Biasco G, Italian Liver Cancer (ITA.LI.CA) Group (2013) Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study. Oncologist 18:1256–1257
4. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430
5. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236
6. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G, Resorce I (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56–66
7. Casadei Gardini A, Foca F, Scartozzi M, Silvestris N, Tamburini E, Faloppi L, Brunetti O, Rudnas B, Pisconti S, Valgiusti M, Marisi G, Foschi FG, Ercolani G, Tassinari D, Cascinu S, Frassineti GL (2017) Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. Sci Rep 7:42499
8. Common Terminology Criteria for Adverse Events (CTCAE) (2009) Version 4.0 Published: May 28, 2009 (v4.03: June 14, 2010)
9. Cramarossa G, Lee EK, Sivanathan L, Georgsdottir S, Lien K, Santos KD, Chan K, Emmenegger U (2014) A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials. Biomark Med 8:893–911
10. D’Agostino RB Jr (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265–2281
11. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943
12. Farrag A (2012) Efficacy and toxicity of metronomic capecitabine in advanced hepatocellular carcinoma. J Cancer Ther 3:71–77
13. Finn RS, Kang YK, Mulcahy M, Polite BN, Lim HY, Walters I, Baudelet C, Manekas D, Park JW (2012) Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 18:2090–2098
14. Granito A, Marinelli S, Terzi E, Piscaglia F, Renzulli M, Venerandi L, Benevento F, Bolondi L (2015) Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. Dig Liver Dis 47:518–522
15. He SL, Shen J, Sun XJ, Zhu XJ, Liu LM, Dong JC (2013) Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. World J Gastroenterol 19:4552–4558
16. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, Cammà C, Colombo M; SOFIA (Sorafenib Italian Assessment) study group (2011) Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 54:2055–2063
17. Kareva I, Waxman DJ, Lakka Klement G (2015) Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett 358:100–106
18. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423–436
19. Lee JO, Lee KW, Oh DY, Kim JH, Im SA, Kim TY, Bang YJ (2009) Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol 20:1402–1407
20. Lee IC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lin HC, Lee FY, Huang YH (2015) Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. Medicine (Baltimore) 94:e688
21. Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60
22. Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ (2014) GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafenib): second interim analysis. Int J Clin Pract 68:609–617
23. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390
24. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW (2013) Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 31:3509–3516
25. Llovet JM, Villanueva A, Lachenmayer A, Finn RS (2015) Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 12:436
26. Marinelli S, Granito A, Piscaglia F, Renzulli M, Stagni A, Bolondi L (2013) Metronomic capecitabine in patients with hepatocellular carcinoma unresponsive to or ineligible for sorafenib treatment: report of two cases. Hepat Mon 13:e11721
27. Murer F, Pozzan C, Peserico G, Farinati F (2016) Capecitabine in advanced hepatocellular carcinoma. Dig Liver Dis 48:1260–1261
28. Pasquier E, Kavallaris M, André N (2010) Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7:455–465
29. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer II, Wolff RA, Charnsangavej C, Brown TD (2004) Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101:578–586
30. Reig M, Rimola J, Torres F, Darnell A, Rodriguez-Lope C, Forner A, Llarch N, Ríos J, Ayuso C, Bruix J (2013) Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology 58:2023–2031
31. Shao YY, Wu CH, Lu LC, Chan SY, Ma YY, Yen FC, Hsu CH, Cheng AL (2014) Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy. J Hepatol 60:313–318
32. Walko CM, Lindley C (2005) Capecitabine: a review. Clin Ther 27:23–44
33. Xia Y, Qiu Y, Li J, Shi L, Wang K, Xi T, Shen F, Yan Z, Wu M (2010) Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. Ann Surg Oncol 17:3137–3144
34. Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RT, Blanc JF, Vogel A, Chen CL, Dorval E, Peck-Radosavljevic M, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB, Chen LT (2014) Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 312:57–67
35. Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators (2015) Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 16:859–870